UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DCD.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

~~Securities~~Date ~~Exchange~~of ~~Act~~report (Date of ~~1934~~earliest event reported): March 3, 2026

Date of report (Date of earliest event reported): February 6, 2026

Roivant Sciences Ltd.

(Exact ~~Name~~name of ~~Registrant~~registrant as ~~Specified~~specified in ~~Charter~~its charter)

Bermuda	001-40782	98-1173944	~~001-40782~~	~~98-1173944~~
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(I.R.S. Employer Identification No.)
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

7th Floor

50 Broadway

London SW1H 0DB

United Kingdom

1 Pennsylvania Plaza

Floor 54

New York, ~~NY101191~~NY 10119

United States¹

Viaduktstrasse 8

4051 Basel

Switzerland¹

(~~Addresses~~Address of ~~Principal~~principal ~~Executive~~executive ~~Offices~~offices, and Zip Code)

+44 207 400 -3347

Registrant’s Telephone Number, Including Area Code

Not Applicable

(Former ~~Name~~name or ~~Former~~former ~~Address~~address, if ~~Changed~~changed ~~Since~~since ~~Last~~last ~~Report~~report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

			o			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
			o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
			o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
			o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Shares, $0.0000000341740141 per share		ROIV		The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (~~17 CFR~~ §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (~~17 CFR~~ §240.12b-2 of this chapter).

Emerging growth company o☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o☐

¹	Addresses of wholly-owned subsidiaries of the Registrant.

Item 27.0201. ~~Results~~ ofRegulation ~~Operations~~FD ~~and Financial Condition.~~Disclosure

On ~~February~~March 63, 2026, Roivant Sciences Ltd. (the “Company”) issued a press release announcing ~~its~~that ~~financial~~the ~~results~~U.S. Food and Drug Administration has accepted the New Drug Application (“NDA”) for brepocitinib for the ~~fiscal~~treatment ~~quarter~~of ~~ended~~dermatomyositis ~~December~~filed 31by the Company’s subsidiary, ~~2025~~Priovant Therapeutics, and has granted the NDA Priority Review. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information ~~set~~furnished ~~forth~~ under this “Item 27.~~02.~~01, ~~Results of Operations and Financial Condition” (~~including Exhibit 99.1), shall not be deemed ~~to be~~ “filed” for ~~the~~ purposes of Section 18 of the Securities Exchange Act of 1934, asor subject ~~amended,~~to ~~nor~~the ~~shall~~liabilities itof bethat ~~incorporated~~section byor ~~reference~~Sections in11 ~~any~~and ~~filing~~12(a)(2) ~~made~~of by the ~~Company pursuant to the~~ Securities Act of 1933. The information in this Item 7.01, asincluding ~~amended~~Exhibit 99.1, shall not be deemed incorporated by reference into any other ~~than~~filing towith the ~~extent~~U.S. Securities ~~that~~and ~~such~~Exchange ~~filing~~Commission ~~incorporates~~made by ~~reference~~the ~~any~~Company, whether made before or ~~all~~after the date hereof, regardless of ~~such~~any ~~information~~general byincorporation ~~express~~language ~~reference~~in ~~thereto~~such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description of Exhibit	~~Description of Exhibit~~
99.1	Press Release, dated March 3, 2026.	~~Roivant Science Ltd. Press Release, dated February 6, 2026~~
104	Cover Page Interactive Data File (embedded with Inline XBRL document).	~~Cover Page Interactive Data File (embedded with Inline XBRL document)~~

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ROIVANT SCIENCES LTD.
By:	/s/ Keyur Parekh	~~/s/ Keyur Parekh~~
Name: Keyur Parekh
Title: Authorized Signatory
Dated: February 6, 2026
Dated: March 3, 2026

Filing Compare · Roivant Sciences Ltd.